Want to join the conversation?
$VRTX reported total CF product revenues of approx. $426MM in 2Q16 versus $155MM in 2Q15. Orkambi drug sales were $245MM. Kalydeco drug sales were up $25MM to $108MM. Operating expenses rose in 2Q16, due to increased costs related to the progression of CF pipeline and increased investments in global commercial support for the launch of Orkambi.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.